Details

---

Content: Mirabegron 25mg

Manufacturer: Astellas Pharma Europe B.V., Netherlands

Marketing Authorization Holder: Astellas Pharma Malaysia Sdn Bhd

Product Registration Number (MAL): MAL15015106ACRZ

Content: A prolonged-release film-coated tablet designed for oral administration

• Indications

  Betmiga is indicated for the symptomatic treatment of

• Urgency (sudden, strong need to urinate)

• Increased micturition frequency (frequent urination)

• These symptoms may occur in adult patients with overactive bladder (OAB) syndrome.

• Urgency incontinence (involuntary leakage of urine)

• Dosage: The recommended starting dose is 25 mg once daily.

• Administration: Swallow the tablet whole with water; do not chew, crush, or divide.

• With or Without Food: May be taken with or without food.

• Consistency: Take at the same time each day to help remember.

• Missed Dose: If more than 12 hours have passed since the missed dose, skip it and take the next dose at the usual time.